A Wrong Result and a Data Breach Are Both Patient Harm.
Protecting clinical, diagnostic, molecular, and genomic testing laboratories
Diagnostics and genomics labs turn a specimen into a result that a physician and patient act on — which means two very different things can go wrong, and both end in patient harm. A false, missed, or misinterpreted result can lead to a wrong or delayed diagnosis and a serious bodily-injury claim. And the enormous, uniquely sensitive datasets these labs hold — protected health information layered with genetic and genomic data — make them a prime target for breach, with statutory exposures that run well beyond an ordinary health-data incident. Modern molecular and next-generation-sequencing labs add still more: lab-developed tests now moving under FDA device regulation, bioinformatics pipelines whose algorithms interpret variants, and an irreplaceable biobank of patient samples. This class shares a foundation with the general medical laboratory but carries a distinct genomic, software, and products profile that a standard lab or medical-malpractice policy was never written for.
Properly built coverage protects the accuracy of the result, the privacy of the data behind it, and the lab itself.
The Diagnostics Lab's Signature Exposures
The defining exposure is professional liability for the result — a false negative that misses a cancer, a false positive that triggers unnecessary treatment, or a misread variant that sends care in the wrong direction. Running alongside it is data exposure of a special kind: genetic and genomic information is protected not only by HIPAA but by the Genetic Information Nondiscrimination Act and a fast-growing wave of state genetic-privacy laws, so a genomic breach carries statutory and class-action exposure an ordinary health record does not. For labs that develop their own tests, the FDA's move to regulate lab-developed tests as medical devices adds a products-liability dimension, and the bioinformatics and biobank behind every genomic result round out a profile where a wrong answer and a data breach are equally serious.
Key Risks in Diagnostics & Genomics Lab Operations
Diagnostics and genomics labs face exposure related to:
A false, missed, or misinterpreted result that leads to a wrong or delayed diagnosis
Errors in bioinformatics pipelines, variant interpretation, and software-driven results
Injury alleged from a lab-developed test or diagnostic product the lab offers
Breach of protected health information and genetic or genomic data
Genetic-privacy claims under GINA and state genetic-privacy and biometric laws
Loss of an irreplaceable specimen biobank from equipment failure or contamination
Biohazard and specimen-handling exposures across the lab
The wrong result and the genomic-data breach are the two exposures that most define the lab.
Core Coverages for Diagnostics & Genomics Labs
A properly built diagnostics and genomics lab program typically includes:
Professional Liability / Laboratory E&O — Covers claims from a false, missed, or misreported result that leads to a wrong or delayed diagnosis.
Products Liability — Responds to injury alleged from a lab-developed test or diagnostic product the lab offers.
Cyber & Genetic Privacy — Protects genomic datasets and protected health information, and responds to genetic-privacy, breach, and class-action claims.
Technology E&O / Bioinformatics — Covers errors in algorithms, variant interpretation, and the software that drives a result.
Commercial Property & Equipment Breakdown — Insures sequencers, instruments, cold storage, and the systems a failure would take offline.
Specimen & Property of Others — Covers irreplaceable patient samples, the biobank, and sponsor-owned materials in the lab's care.
Pollution & Biohazard Liability — Responds to specimen, reagent, and biological contamination exposures.
General Liability — Protects against third-party injury and property damage at the laboratory.
Workers' Compensation — Covers technicians and staff handling specimens, reagents, and equipment.
What's Commonly Overlooked
Diagnostics and genomics lab programs are most often weakened by:
A medical-malpractice or general E&O policy that excludes the lab-developed-test products exposure
Genetic-privacy exposure treated as ordinary HIPAA, ignoring GINA and state genetic-privacy laws
No technology E&O for the bioinformatics and algorithms that interpret genomic results
Cyber limits sized for a small practice, not for a lab holding millions of genomic records
No valuation or coverage for an irreplaceable specimen biobank
The gap that hurts most is leaving the genomic-privacy and lab-developed-test exposures to a policy built for a routine lab.
Real-World Claim Examples
A missed finding on a diagnostic or genomic test leads to a delayed cancer diagnosis
A misinterpreted variant sends a patient toward the wrong treatment
A breach exposes the genomic profiles and identities of hundreds of thousands of patients
A class action is brought under a state genetic-privacy or biometric statute
A sequencer or cold-storage failure destroys an irreplaceable specimen biobank
A single wrong-result claim or a genomic breach can reach catastrophic severity and class-action scale.
Regulatory & Compliance Context
Clinical labs operate under the Clinical Laboratory Improvement Amendments (CLIA) and, commonly, College of American Pathologists (CAP) accreditation, with HIPAA governing the privacy and security of patient data. Genetic information carries an added layer: the Genetic Information Nondiscrimination Act (GINA) plus state genetic-privacy, biometric, and consumer-genetic-data laws that continue to expand. For labs that develop and run their own tests, the FDA has moved to regulate lab-developed tests as medical devices under a phased framework, pulling many labs into device quality and reporting obligations — and into products-liability exposure. Underwriters expect this compliance posture documented, and a clean accreditation, quality, and data-security record is central to placement.
Why Proper Placement Matters
Test menu and data footprint drive the program. A routine clinical chemistry lab, a molecular and next-generation-sequencing lab, and a consumer-genomics company present very different professional, products, and privacy exposures, and the coverage has to match both the science and the scale of the data. Underwriters weigh the test menu and whether the lab develops its own tests, the volume and sensitivity of the genomic data held, the bioinformatics and software in use, CLIA and CAP status, and the lab's security controls. Much of this risk — the products, technology, and genetic-privacy exposures — is written in specialty and excess-and-surplus-lines markets built for molecular and genomic labs. Presenting documented accreditation, strong data security, and clear test validation is what secures coverage that reaches the exposures a general lab policy leaves out.
Our Approach
At Cory Washington & Co., we build diagnostics and genomics lab programs around both the result and the data — coordinating laboratory professional liability, lab-developed-test products coverage, technology E&O for the bioinformatics, and cyber written for genomic-scale genetic-privacy exposure, rather than a policy built for a routine lab. We size cyber and products limits to the real data footprint and test menu, and document the biobank so it can actually be covered. We also insure the businesses alongside you, including the general medical laboratory, biotech R&D firms, clinical trial programs, and the broader life sciences company.
A wrong result and a data breach are both patient harm — we build coverage that stands behind the accuracy of your science and the privacy of everything behind it.
All insurance descriptions on this website are provided by Cory Washington & Co. LLC strictly for general informational purposes. They are not intended to be, and should not be relied upon as, legal, financial, or insurance advice. The information presented is general in nature and does not guarantee the availability, terms, conditions, or scope of any insurance coverage. Actual coverage is determined solely by the specific policy language issued by the insurer and remains subject to underwriting approval. Nothing on this website creates or implies an agent-client relationship, binds coverage, or alters any existing policy. Cory Washington & Co. LLC expressly disclaims any liability for actions taken, or not taken, based on the content provided here. For advice regarding your particular situation, please consult directly with a licensed insurance professional at Cory Washington & Co. LLC or another qualified insurance professional, and always review your policy documents in full.
See the coverages a diagnostics & genomics lab business may carry — core, prevalent, and situational — plus the gap most often missed, in the Diagnostics & Genomics Lab Coverage Checklist.
Complete the Diagnostics & Genomics Lab Supplemental online in a few guided steps, download the fillable PDF, or browse all applications.
Frequently Asked Questions
How do I get diagnostics & genomics lab insurance through Cory Washington & Co.?
Request a quote or contact our team. We start with a short conversation about your operations, analyze your exposures, then negotiate diagnostics & genomics lab insurance across multiple carriers that compete for your account and present options with the trade-offs explained. Cory Washington & Co. LLC is licensed in all 50 states.
What does diagnostics & genomics lab insurance cost?
Premiums vary from business to business. The main drivers of diagnostics & genomics lab insurance pricing are the nature of your operations, your revenue and payroll, your loss history, and the limits you carry. Rather than quote a flat figure, we negotiate across several markets and walk you through the options, so you only pay for the protection you actually need.
Is diagnostics & genomics lab insurance required?
Requirements vary. Diagnostics & genomics lab insurance may be mandated by statute, or required under your contracts, leases, or loan agreements — and in many cases it is simply prudent given the risks involved. We look at your specific obligations and exposures, then recommend the coverage and limits that fit.
What if another agency has already declined or non-renewed my coverage?
Difficult, specialty, and previously-declined placements are a core part of our work. We access excess & surplus (E&S) and specialty markets that many generalist agencies cannot, and we explain the trade-offs clearly so you can decide with confidence.
Available in all 50 states. See how requirements differ in California, Texas, Florida, New York, or choose your state.